Observed nAb titers against Omicron BA.4/BA.5 (a) and ancestral SARS-CoV-2 (D614G) (b) after 50 g of mRNA-1273.222 and mRNA-1273 administered as second booster doses. Pseudovirus nAb GMTs are provided for all participants regardless of SARS-CoV-2 infection prebooster status, and those with and without previous SARS-CoV-2 infection prebooster. Data are from participants with nonmissing data at the timepoint. Seven participants in mRNA-1273.222 and eight participants in the mRNA-1273 group were missing prebooster SARS-CoV-2 status in the per protocol immunogenicity set. Antibody values reported as below the LLOQ (18.5 (1.3 in log 10 scale) for ancestral SARS-CoV-2 (D614G) and 36.7 (1.6 in log 10 scale) for Omicron BA.4/BA.5) were replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ 45,118 (4.7 in log 10 scale) for ancestral SARS-CoV-2 (D614G); 13,705 (4.1 in log 10 scale) for Omicron BA.4/BA.5) were replaced by the ULOQ if actual values were not available. 95% CIs were calculated based on the t -distribution of the log-transformed values for GM value, then back-transformed to the original scale for presentation. Data for observed nAb GMTs by prior SARS-CoV-2 infection are provided in Supplementary Table 7.
